Thomas J. Schaefer - 01 Aug 2024 Form 4 Insider Report for Arcadia Biosciences, Inc. (RKDA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
20 Aug 2024, 20:05:54 UTC
Prior SEC filing
05 Feb 2024
Next SEC filing
21 Aug 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Thomas J. Schaefer, by Attorney-in-fact, Solaeta Chan

Key filing fact

Thomas J. Schaefer filed Form 4 for Arcadia Biosciences, Inc. (RKDA) on 20 Aug 2024.

Key facts

  • This page summarizes Thomas J. Schaefer's Form 4 filing for Arcadia Biosciences, Inc. (RKDA).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 20 Aug 2024, 20:05.

Change

  • Previous filing in this sequence was filed on 05 Feb 2024.
  • Current net transaction value: +$1,442.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RKDA transaction

Common Stock

Purchase

Transaction value
$1,442
Shares
+700
Change %
+49%
Price
$2.06
Shares after
2,119
Date
01 Aug 2024
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects the purchase of 700 shares of the Issuer's common stock on 8/1/24 at a per share purchase price of $2.06 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan ("ESPP"). This transaction is exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's common stock.

Footnote F2

The amount includes the 2015 Employee Stock Purchase Plan ("ESPP") purchases, for the purchase periods from February 1, 2021 to August 1, 2024. These transactions were exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's Common Stock on the date of each respective purchase.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .